049 | Global Insolvency Outlook 2023-25: From...

We just published the fifth edition of our Allianz Trade Global Survey, where we asked 6,000 companies in 13 countries, including the US, France, Germany, China, India and Vietnam, about their outlook for the year ahead. And because we spoke to them in February and March, we were ...  Show more

25% of the world’s hydrocarbon flows pass through one narrow waterway—the Strait of Hormuz. That’s a quarter of global energy supply relying on a single chokepoint. Today, we’re diving into how the ongoing conflict in the Middle East is shaking up the global economy, and why this ...  Show more

More than 1bn people around the world are obese. That means there should be extraordinary demand for drugs to cure or mitigate the condition. Novo Nordisk is now Europe’s most valuable company and Eli Lilly’s market value has more than doubled. Both make the “miracle” drugs th ...

Apple & Amazon the latest big tech names to report results. The headlines from the company conference calls, and what top tech analyst Gene Munster sees in store for the group. Plus Eli Lilly jumping as its obesity drug sales soar. How the company is moving the needle in the w ...

FDA’s removal of GLP-1 drugs from the shortage list ends supplemental compounding, shifting patient access back to branded semaglutide and tirzepatide. Featuring: Sara Heath, executive editor, Xtelligent Healthcare Alivia Kaylor, senior editor of Pharma Life Sciences, Xtelligent ...  Show more

Dr. Marty Makary has criticized the Food and Drug Administration for being "captured" by Big Food and Big Pharma. Now, the surgeon and former professor is in charge. In an interview with host Jessica Mendoza, the new FDA head talks about food dyes, AI, vaccines and the big change ...  Show more